ORIC · US market

ORIC Pharmaceuticals Inc

Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.

Market cap US$1.30bnFinancials dated 30 June 2026Price dated 1 October 2026

Core valuation

Trailing P/E-9.25×
Latest-quarter run-rate P/E-7.82×
Trailing P/SUnavailable
Latest-quarter run-rate P/SUnavailable

Calculation inputs

Trailing earnings
-US$140.35m
Latest-quarter run-rate earnings
-US$165.97m
Latest fiscal-year earnings
-US$129.47m
Trailing revenue
US$0.00
Latest-quarter run-rate revenue
US$0.00
Latest fiscal-year revenue
Unavailable

Featured ETF and mutual-fund exposure

These public funds report this company in their latest disclosed holdings.

Sources and limitations

Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.

Open financial source

Financials as of 30 June 2026. Informational research, not investment advice.